Loading…
Clinical picture, outcome, and predictive factors of lymphoma in primary Sjogren's syndrome. Results from a harmonized dataset (1981-2021)
Primary Sjögren's Syndrome (pSS) carries the highest risk for non-Hodgkin's lymphoma (NHL) development among systemic autoimmune diseases. However, the paucity of data on the long-term survival of those patients and the lack of established predictors for each lymphoma histologic subtype pr...
Saved in:
Published in: | Rheumatology (Oxford, England) England), 2022-08, Vol.61 (9), p.3576-3585 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c307t-b314b9171f2e4e255f20ea6bf71204640050635400740b395d28d80d0d00bae13 |
---|---|
cites | cdi_FETCH-LOGICAL-c307t-b314b9171f2e4e255f20ea6bf71204640050635400740b395d28d80d0d00bae13 |
container_end_page | 3585 |
container_issue | 9 |
container_start_page | 3576 |
container_title | Rheumatology (Oxford, England) |
container_volume | 61 |
creator | Chatzis, Loukas G Stergiou, Ioanna E Goules, Andreas V Pezoulas, Vasilis Tsourouflis, Gerasimos Fotiadis, Dimitrios Tzioufas, Athanasios G Voulgarelis, Michael |
description | Primary Sjögren's Syndrome (pSS) carries the highest risk for non-Hodgkin's lymphoma (NHL) development among systemic autoimmune diseases. However, the paucity of data on the long-term survival of those patients and the lack of established predictors for each lymphoma histologic subtype prompted our present study.
We retrospectively analyzed 121 patients diagnosed with NHL according to the WHO classification criteria. All patients fulfilled the 2016 ACR-EULAR classification criteria for pSS. Cumulative clinical, laboratory, radiologic, treatment regimens and histologic data were recorded, harmonized, and analyzed. Overall survival (OS) and event free survival (EFS) curves were calculated. A Mucosa Associated Lymphoid Tissue lymphoma (MALTL) prediction model was developed by applying innovative data driven analysis of clinical features present at the time of pSS diagnosis.
MALTLs constituted the majority of lymphomas (92/121, 76,0%) followed by Diffuse Large B Cell Lymphomas (DLBCL) (11/121, 9.0%) and Nodal Marginal Zone Lymphomas (NMZL) (8/121, 7%). MALTLs show salivary glands localization, limited disease and often bone marrow and nodal involvement. The 10-year OS and EFS rates were 79% and 45,5% for MALTLs, 40,9% and 24,2% for DLBCL and 46% and 31% for NMZL. Cryoglobulinemia, focus score and the total EULAR SS Disease Activity Index (ESSDAI) composite index at pSS diagnosis were proven independent MALTL predictors. Even though MALTLs have a comparatively good survival outlook, they are accompanied by frequent events throughout their clinical course.
Common features of pSS, present at diagnosis, can predict future lymphomagenesis meriting a more intensive follow up plan. |
doi_str_mv | 10.1093/rheumatology/keab939 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2613294327</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2613294327</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-b314b9171f2e4e255f20ea6bf71204640050635400740b395d28d80d0d00bae13</originalsourceid><addsrcrecordid>eNpNUdtKw0AQXUSxtfoHIvtmBdPuLbdHKd6gIHh5DpvspE1NsnV3I8RP8KtdaSwyD2eGOWeGmYPQOSUzSlI-N2voGul0rVf9_B1knvL0AI2piFhAOGeH-5yJETqxdkMICSlPjtGIi1SQhLIx-l7UVVsVssbbqnCdgWusO1foxieyVXhrQPlG9Qm4lIXTxmJd4rpvtmvdSFy1nlE10vT4ZaNXBtpLi23fKuMnzPAz2K52Fpe-xBKvpWl0W32Bwko6acHhKU0TGjDC6NUpOiplbeFswAl6u7t9XTwEy6f7x8XNMig4iV2QcyrylMa0ZCCAhWHJCMgoL2PKiIiEP5JEPPQYC5LzNFQsUQlRPkgugfIJmu7mbo3-6MC6rKlsAXUtW9CdzVhEOUsFZ7Gnih21MNpaA2U2XJtRkv26kP13IRtc8LKLYUOXN6D2or-38x8MUofL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2613294327</pqid></control><display><type>article</type><title>Clinical picture, outcome, and predictive factors of lymphoma in primary Sjogren's syndrome. Results from a harmonized dataset (1981-2021)</title><source>Oxford Journals Online</source><source>Alma/SFX Local Collection</source><creator>Chatzis, Loukas G ; Stergiou, Ioanna E ; Goules, Andreas V ; Pezoulas, Vasilis ; Tsourouflis, Gerasimos ; Fotiadis, Dimitrios ; Tzioufas, Athanasios G ; Voulgarelis, Michael</creator><creatorcontrib>Chatzis, Loukas G ; Stergiou, Ioanna E ; Goules, Andreas V ; Pezoulas, Vasilis ; Tsourouflis, Gerasimos ; Fotiadis, Dimitrios ; Tzioufas, Athanasios G ; Voulgarelis, Michael</creatorcontrib><description>Primary Sjögren's Syndrome (pSS) carries the highest risk for non-Hodgkin's lymphoma (NHL) development among systemic autoimmune diseases. However, the paucity of data on the long-term survival of those patients and the lack of established predictors for each lymphoma histologic subtype prompted our present study.
We retrospectively analyzed 121 patients diagnosed with NHL according to the WHO classification criteria. All patients fulfilled the 2016 ACR-EULAR classification criteria for pSS. Cumulative clinical, laboratory, radiologic, treatment regimens and histologic data were recorded, harmonized, and analyzed. Overall survival (OS) and event free survival (EFS) curves were calculated. A Mucosa Associated Lymphoid Tissue lymphoma (MALTL) prediction model was developed by applying innovative data driven analysis of clinical features present at the time of pSS diagnosis.
MALTLs constituted the majority of lymphomas (92/121, 76,0%) followed by Diffuse Large B Cell Lymphomas (DLBCL) (11/121, 9.0%) and Nodal Marginal Zone Lymphomas (NMZL) (8/121, 7%). MALTLs show salivary glands localization, limited disease and often bone marrow and nodal involvement. The 10-year OS and EFS rates were 79% and 45,5% for MALTLs, 40,9% and 24,2% for DLBCL and 46% and 31% for NMZL. Cryoglobulinemia, focus score and the total EULAR SS Disease Activity Index (ESSDAI) composite index at pSS diagnosis were proven independent MALTL predictors. Even though MALTLs have a comparatively good survival outlook, they are accompanied by frequent events throughout their clinical course.
Common features of pSS, present at diagnosis, can predict future lymphomagenesis meriting a more intensive follow up plan.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/keab939</identifier><identifier>PMID: 34940812</identifier><language>eng</language><publisher>England</publisher><ispartof>Rheumatology (Oxford, England), 2022-08, Vol.61 (9), p.3576-3585</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c307t-b314b9171f2e4e255f20ea6bf71204640050635400740b395d28d80d0d00bae13</citedby><cites>FETCH-LOGICAL-c307t-b314b9171f2e4e255f20ea6bf71204640050635400740b395d28d80d0d00bae13</cites><orcidid>0000-0002-2832-0116 ; 0000-0002-9977-4035</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34940812$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chatzis, Loukas G</creatorcontrib><creatorcontrib>Stergiou, Ioanna E</creatorcontrib><creatorcontrib>Goules, Andreas V</creatorcontrib><creatorcontrib>Pezoulas, Vasilis</creatorcontrib><creatorcontrib>Tsourouflis, Gerasimos</creatorcontrib><creatorcontrib>Fotiadis, Dimitrios</creatorcontrib><creatorcontrib>Tzioufas, Athanasios G</creatorcontrib><creatorcontrib>Voulgarelis, Michael</creatorcontrib><title>Clinical picture, outcome, and predictive factors of lymphoma in primary Sjogren's syndrome. Results from a harmonized dataset (1981-2021)</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><description>Primary Sjögren's Syndrome (pSS) carries the highest risk for non-Hodgkin's lymphoma (NHL) development among systemic autoimmune diseases. However, the paucity of data on the long-term survival of those patients and the lack of established predictors for each lymphoma histologic subtype prompted our present study.
We retrospectively analyzed 121 patients diagnosed with NHL according to the WHO classification criteria. All patients fulfilled the 2016 ACR-EULAR classification criteria for pSS. Cumulative clinical, laboratory, radiologic, treatment regimens and histologic data were recorded, harmonized, and analyzed. Overall survival (OS) and event free survival (EFS) curves were calculated. A Mucosa Associated Lymphoid Tissue lymphoma (MALTL) prediction model was developed by applying innovative data driven analysis of clinical features present at the time of pSS diagnosis.
MALTLs constituted the majority of lymphomas (92/121, 76,0%) followed by Diffuse Large B Cell Lymphomas (DLBCL) (11/121, 9.0%) and Nodal Marginal Zone Lymphomas (NMZL) (8/121, 7%). MALTLs show salivary glands localization, limited disease and often bone marrow and nodal involvement. The 10-year OS and EFS rates were 79% and 45,5% for MALTLs, 40,9% and 24,2% for DLBCL and 46% and 31% for NMZL. Cryoglobulinemia, focus score and the total EULAR SS Disease Activity Index (ESSDAI) composite index at pSS diagnosis were proven independent MALTL predictors. Even though MALTLs have a comparatively good survival outlook, they are accompanied by frequent events throughout their clinical course.
Common features of pSS, present at diagnosis, can predict future lymphomagenesis meriting a more intensive follow up plan.</description><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpNUdtKw0AQXUSxtfoHIvtmBdPuLbdHKd6gIHh5DpvspE1NsnV3I8RP8KtdaSwyD2eGOWeGmYPQOSUzSlI-N2voGul0rVf9_B1knvL0AI2piFhAOGeH-5yJETqxdkMICSlPjtGIi1SQhLIx-l7UVVsVssbbqnCdgWusO1foxieyVXhrQPlG9Qm4lIXTxmJd4rpvtmvdSFy1nlE10vT4ZaNXBtpLi23fKuMnzPAz2K52Fpe-xBKvpWl0W32Bwko6acHhKU0TGjDC6NUpOiplbeFswAl6u7t9XTwEy6f7x8XNMig4iV2QcyrylMa0ZCCAhWHJCMgoL2PKiIiEP5JEPPQYC5LzNFQsUQlRPkgugfIJmu7mbo3-6MC6rKlsAXUtW9CdzVhEOUsFZ7Gnih21MNpaA2U2XJtRkv26kP13IRtc8LKLYUOXN6D2or-38x8MUofL</recordid><startdate>20220830</startdate><enddate>20220830</enddate><creator>Chatzis, Loukas G</creator><creator>Stergiou, Ioanna E</creator><creator>Goules, Andreas V</creator><creator>Pezoulas, Vasilis</creator><creator>Tsourouflis, Gerasimos</creator><creator>Fotiadis, Dimitrios</creator><creator>Tzioufas, Athanasios G</creator><creator>Voulgarelis, Michael</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2832-0116</orcidid><orcidid>https://orcid.org/0000-0002-9977-4035</orcidid></search><sort><creationdate>20220830</creationdate><title>Clinical picture, outcome, and predictive factors of lymphoma in primary Sjogren's syndrome. Results from a harmonized dataset (1981-2021)</title><author>Chatzis, Loukas G ; Stergiou, Ioanna E ; Goules, Andreas V ; Pezoulas, Vasilis ; Tsourouflis, Gerasimos ; Fotiadis, Dimitrios ; Tzioufas, Athanasios G ; Voulgarelis, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-b314b9171f2e4e255f20ea6bf71204640050635400740b395d28d80d0d00bae13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chatzis, Loukas G</creatorcontrib><creatorcontrib>Stergiou, Ioanna E</creatorcontrib><creatorcontrib>Goules, Andreas V</creatorcontrib><creatorcontrib>Pezoulas, Vasilis</creatorcontrib><creatorcontrib>Tsourouflis, Gerasimos</creatorcontrib><creatorcontrib>Fotiadis, Dimitrios</creatorcontrib><creatorcontrib>Tzioufas, Athanasios G</creatorcontrib><creatorcontrib>Voulgarelis, Michael</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chatzis, Loukas G</au><au>Stergiou, Ioanna E</au><au>Goules, Andreas V</au><au>Pezoulas, Vasilis</au><au>Tsourouflis, Gerasimos</au><au>Fotiadis, Dimitrios</au><au>Tzioufas, Athanasios G</au><au>Voulgarelis, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical picture, outcome, and predictive factors of lymphoma in primary Sjogren's syndrome. Results from a harmonized dataset (1981-2021)</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2022-08-30</date><risdate>2022</risdate><volume>61</volume><issue>9</issue><spage>3576</spage><epage>3585</epage><pages>3576-3585</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>Primary Sjögren's Syndrome (pSS) carries the highest risk for non-Hodgkin's lymphoma (NHL) development among systemic autoimmune diseases. However, the paucity of data on the long-term survival of those patients and the lack of established predictors for each lymphoma histologic subtype prompted our present study.
We retrospectively analyzed 121 patients diagnosed with NHL according to the WHO classification criteria. All patients fulfilled the 2016 ACR-EULAR classification criteria for pSS. Cumulative clinical, laboratory, radiologic, treatment regimens and histologic data were recorded, harmonized, and analyzed. Overall survival (OS) and event free survival (EFS) curves were calculated. A Mucosa Associated Lymphoid Tissue lymphoma (MALTL) prediction model was developed by applying innovative data driven analysis of clinical features present at the time of pSS diagnosis.
MALTLs constituted the majority of lymphomas (92/121, 76,0%) followed by Diffuse Large B Cell Lymphomas (DLBCL) (11/121, 9.0%) and Nodal Marginal Zone Lymphomas (NMZL) (8/121, 7%). MALTLs show salivary glands localization, limited disease and often bone marrow and nodal involvement. The 10-year OS and EFS rates were 79% and 45,5% for MALTLs, 40,9% and 24,2% for DLBCL and 46% and 31% for NMZL. Cryoglobulinemia, focus score and the total EULAR SS Disease Activity Index (ESSDAI) composite index at pSS diagnosis were proven independent MALTL predictors. Even though MALTLs have a comparatively good survival outlook, they are accompanied by frequent events throughout their clinical course.
Common features of pSS, present at diagnosis, can predict future lymphomagenesis meriting a more intensive follow up plan.</abstract><cop>England</cop><pmid>34940812</pmid><doi>10.1093/rheumatology/keab939</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-2832-0116</orcidid><orcidid>https://orcid.org/0000-0002-9977-4035</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1462-0324 |
ispartof | Rheumatology (Oxford, England), 2022-08, Vol.61 (9), p.3576-3585 |
issn | 1462-0324 1462-0332 |
language | eng |
recordid | cdi_proquest_miscellaneous_2613294327 |
source | Oxford Journals Online; Alma/SFX Local Collection |
title | Clinical picture, outcome, and predictive factors of lymphoma in primary Sjogren's syndrome. Results from a harmonized dataset (1981-2021) |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A17%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20picture,%20outcome,%20and%20predictive%20factors%20of%20lymphoma%20in%20primary%20Sjogren's%20syndrome.%20Results%20from%20a%20harmonized%20dataset%20(1981-2021)&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Chatzis,%20Loukas%20G&rft.date=2022-08-30&rft.volume=61&rft.issue=9&rft.spage=3576&rft.epage=3585&rft.pages=3576-3585&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/keab939&rft_dat=%3Cproquest_cross%3E2613294327%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c307t-b314b9171f2e4e255f20ea6bf71204640050635400740b395d28d80d0d00bae13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2613294327&rft_id=info:pmid/34940812&rfr_iscdi=true |